Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients

被引:11
|
作者
Moore, Sara [1 ,2 ]
Leung, Bonnie [2 ]
Wu, Jonn [1 ,3 ]
Ho, Cheryl [1 ,2 ]
机构
[1] Univ British Columbia, Vancouver, BC V6T 1Z4, Canada
[2] BC Canc, Dept Med Oncol, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada
[3] BC Canc, Dept Radiat Oncol, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada
关键词
Non-small cell lung cancer; Stage II; Inoperable; Real-world; Outcomes; VINORELBINE PLUS CISPLATIN; ADJUVANT CHEMOTHERAPY; POOLED ANALYSIS; PATTERNS; MANAGEMENT; OUTCOMES; NSCLC;
D O I
10.1186/s13014-020-1466-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives Curative intent therapy of stage II NSCLC may include surgical resection or definitive radiotherapy. Primary management with surgery or radiotherapy may be influenced by patient and disease characteristics. We sought to perform a comparison of patients receiving surgery or radical radiation therapy as their curative treatment, and explore the impact of known prognostic factors on outcome. Materials and methods A retrospective review was completed of all patients with stage II NSCLC referred to the BC Cancer Agency from 2005 to 2012. Cases were filtered to identify those receiving curative intent therapy including surgery or radiotherapy. Information was collected on known prognostic and predictive factors. The primary outcome measure was overall survival. We compared survival among patients receiving curative intent radiotherapy versus surgical intervention. Results A total of 535 patients were referred. Of these, 245 (46%) received curative intent surgery, 132 (25%) curative intent radiotherapy, and 158 (30%) did not receive curative therapy. There were significant differences between cohorts with respect to median age, histology, ECOG PS, smoking status, and weight loss. Median OS was significantly different between cohorts: 61.4 m surgery, 26.5 m curative RT, and 13.1 m non-curative therapy. In a case-matched analysis, median OS remained superior for surgery at 101.6 m vs 28.1 m for curative RT. In a multivariate analysis, ECOG PS, weight loss, and treatment cohort all influenced survival. Among patients receiving curative intent radiotherapy, the use of concurrent chemotherapy and RT dose > = 60Gy were associated with improved outcomes. Conclusions Among patients with stage II NSCLC, many are unable to undergo standard of care surgical resection. Radiotherapy provides an inferior yet still curative option in the management of inoperable patients. Further work is needed to optimize outcomes in this population.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I-II non-small-cell lung cancer
    Bonfili, Pierluigi
    Di Staso, Mario
    Gravina, Giovanni Luca
    Franzese, Pietro
    Buonopane, Sergio
    Solda, Francesca
    Festuccia, Claudio
    Tombolini, Vincenzo
    LUNG CANCER, 2010, 67 (01) : 81 - 85
  • [22] Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer
    Lanuti, Michael
    Sharma, Amita
    Digumarthy, Subba R.
    Wright, Cameron D.
    Donahue, Dean M.
    Wain, John C.
    Mathisen, Douglas J.
    Shepard, Jo-Anne O.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2009, 137 (01): : 160 - 166
  • [23] Percutaneous Cryoablation for the Treatment of Medically Inoperable Stage I Non-Small Cell Lung Cancer
    Yamauchi, Yoshikane
    Izumi, Yotaro
    Hashimoto, Kohei
    Yashiro, Hideki
    Inoue, Masanori
    Nakatsuka, Seishi
    Goto, Taichiro
    Anraku, Masaki
    Ohtsuka, Takashi
    Kohno, Mitsutomo
    Kawamura, Masafumi
    Nomori, Hiroaki
    PLOS ONE, 2012, 7 (03):
  • [24] Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer
    Hayakawa, K
    Mitsuhashi, N
    Saito, Y
    Nakayama, Y
    Furuta, M
    Sakurai, H
    Kawashima, M
    Ohno, T
    Nasu, S
    Niibe, H
    LUNG CANCER, 1999, 26 (03) : 137 - 142
  • [25] Percutaneous radiofrequency ablation for medically inoperable patients with clinical stage I non-small cell lung cancer
    Liu, Baodong
    Liu, Lei
    Hu, Mu
    Qian, Kun
    Li, Yuanbo
    THORACIC CANCER, 2015, 6 (03) : 327 - 333
  • [26] The Role of Stereotactic Body Radiotherapy in the Management of Non-Small Cell Lung Cancer: An Emerging Standard for the Medically Inoperable Patient?
    Videtic, Gregory M. M.
    Stephans, Kevin L.
    CURRENT ONCOLOGY REPORTS, 2010, 12 (04) : 235 - 241
  • [27] The Role of Stereotactic Body Radiotherapy in the Management of Non-Small Cell Lung Cancer: An Emerging Standard for the Medically Inoperable Patient?
    Gregory M. M. Videtic
    Kevin L. Stephans
    Current Oncology Reports, 2010, 12 : 235 - 241
  • [28] A phase II study of camrelizumab plus chemotherapy in patients with medically inoperable early-stage non-small cell lung cancer
    Wang, C.
    Zhang, L.
    Li, Y.
    Zhang, Z.
    Yue, D.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S95 - S95
  • [29] The development of stereotactic body radiotherapy (SBRT) for medically inoperable early stage non-small cell lung cancer: an international phenomenon
    Videtic, Gregory M. M.
    JOURNAL OF RADIATION ONCOLOGY, 2012, 1 (01) : 3 - 10
  • [30] Stereotactic body radiotherapy for medically inoperable stage I non-small cell lung cancer: Mature outcome and toxicity results
    Kopek, N.
    Paludan, M.
    Petersen, J.
    Grau, C.
    Hoyer, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S37 - S37